MRCP Part 1 Infectious Diseases Facts
- Crack Medicine

- 5 days ago
- 5 min read
This article presents mrcp part 1 infectious diseases: 50 Rapid-Review Facts to sharpen your recall for the MRCP Part 1 exam. You’ll cover high-yield topics, a short exam-style case and common traps, as well as a practical study checklist from Crack Medicine.
Why this matters
Infectious diseases are a critical component of the MRCP Part 1 exam, set by The Federation of the Royal Colleges of Physicians of the UK. According to the official format page, the exam comprises two three-hour papers of 100 “best of five” MCQs each. thefederation.uk Within this, “Infectious diseases” appears as a sub-specialty with around 14 questions in the blueprint. thefederation.uk For candidates, mastering the infectious diseases section offers a reliable way to secure marks: recognition of pathogens, serology interpretation, antimicrobial principles and travel/tropical medicine. This article from Crack Medicine aims to distil key facts rapidly so you can allocate revision time efficiently.
Scope of Infectious Diseases for MRCP Part 1
Let’s clarify what you need to focus on:
Pathogens and mechanisms: major bacterial, viral, fungal and parasitic infections.
Clinical syndromes: e.g., meningitis, endocarditis, sepsis, HIV-associated infections.
Diagnostics: serology, culture, CSF analysis, travel history clues.
Therapy / resistance: antimicrobial and antiviral classes, mechanism-side-effect pairs.
Public health/travel/tropical: vaccinations, prophylaxis, returning traveller
fever. For exam format reference see the official guide. thefederation.uk
50 Rapid-Review Facts (numbered list)
Here are 50 high-yield facts you can quickly review and memorise for your revision session.
Mycobacterium tuberculosis forms caseating granulomas and is treated by the RIPE regimen.
Ethambutol may cause optic neuritis — test colour vision if using long term.
HIV: opportunistic infections appear in patterns by CD4 count thresholds.
CD4 < 200 cells/mm³ → PCP (Pneumocystis jirovecii) prophylaxis indicated.
HBsAg positive, anti-HBs negative, anti-HBc IgM positive → acute hepatitis B.
Chronic hepatitis C may be silent and detected only via anti-HCV + HCV RNA.
Infective endocarditis: S. aureus is the commonest cause in intravenous drug users.
Duke criteria include major (positive blood cultures, new valvular regurgitation) and minor features.
Sepsis: early recognition and prompt antibiotics within first hour improve outcomes.
Malaria (Plasmodium falciparum) can cause cerebral malaria and requires urgent IV artesunate.
Meningitis CSF: bacterial → low glucose (< ½ plasma), high polymorphs, high protein.
Viral meningitis: lymphocytosis, normal glucose, moderate protein increase.
Vaccines: live attenuated (e.g., MMR) contraindicated in severe immunosuppression.
Beta-lactams inhibit cell-wall synthesis; aminoglycosides affect the 30S ribosome.
Macrolides block the 50S ribosome and are useful for atypical pneumonia.
Resistance: MRSA – altered penicillin-binding protein; ESBL organisms produce extended-spectrum beta-lactamases.
HIV seroconversion may mimic glandular fever (fever, rash, lymphadenopathy).
Travel history: consider Leishmania, dengue, chikungunya, schistosomiasis when returning.
Typhoid fever: Salmonella Typhi; consider rose-spots, relative bradycardia and treat with azithromycin or ceftriaxone.
Leprosy (Mycobacterium leprae): hypopigmented patches with sensory loss; treat with rifampicin + dapsone.
Asplenic patients are at high risk of encapsulated organisms (e.g., pneumococcus) – lifelong penicillin prophylaxis recommended.
Clostridioides difficile infection often follows broad-spectrum antibiotic use; first-line therapy is oral vancomycin.
Viral hepatitis A: faeco-oral route, acute, green vomit/fever/jaundice; vaccine available.
Cytomegalovirus (CMV) retinitis appears when CD4 count falls <50 cells/mm³ in HIV.
Cryptococcus neoformans: causes meningitis in immunocompromised; India-ink stain or cryptococcal antigen useful.
Tuberculous meningitis: CSF shows lymphocytosis, very low glucose, fibrin web; PCR more sensitive than Ziehl-Neelsen.
Strongyloides stercoralis: risk of hyper-infection in steroid/immunosuppressed patients; treat with ivermectin.
Schistosoma haematobium: causes haematuria and bladder cancer risk; detect eggs in urine midday.
Dengue fever: think “break-bone” myalgia, rash, thrombocytopenia; serology IgM/IgG helpful.
Zika virus in pregnant women: microcephaly risk; recent travellers beware.
Listeria monocytogenes: gram-positive bacillus; causes meningitis in neonates, elderly and immunocompromised.
Endocarditis prophylaxis is no longer routine for most dental procedures unless very high risk.
Clostridium perfringens: gas gangrene; crepitus, alpha toxin; surgical emergency.
Tetanus: trismus (“lock-jaw”), opisthotonus; prevention via immunisation + wound management.
Leptospirosis: Weil’s disease (jaundice, renal failure, haemorrhage) after water exposure.
Rabies: almost uniformly fatal once symptomatic; post-exposure prophylaxis critical.
Ebola: high-mortality viral haemorrhagic fever; contact precautions essential.
Influenza antiviral: oseltamivir within 48 hours; immunised high-risk groups.
Pertussis (whooping cough): paroxysmal cough, “whoop”, lymphocytosis; macrolides treat.
Measles: Koplik spots, rash; complications include SSPE, pneumonia.
Varicella zoster: chicken-pox in children, shingles in older; treat with aciclovir, immunise older adults.
Post-exposure prophylaxis for hepatitis B: HBsAg-positive source + unvaccinated → HBV immunoglobulin + vaccine.
Post-exposure prophylaxis for HIV: “within 1-2 hours, up to 72 hours” of exposure.
Pneumocystis jirovecii pneumonia: ground-glass appearance on CT, treat with high-dose co-trimoxazole + steroids if PaO₂ < 9.3 kPa.
HSV encephalitis: temporal-lobe necrosis on MRI, treat early with IV aciclovir.
Acute bacterial sinusitis most common organisms: Streptococcus pneumoniae, Haemophilus influenzae.
MRSA colonisation may require nasal mupirocin + chlorhexidine body wash prior to surgery.
Vancomycin-resistant Enterococcus (VRE): difficult nosocomial infection; linezolid or daptomycin used.
Vaccine-preventable infections: >90 % measles elimination requires high community coverage; UK schedules matter.
Multi-drug-resistant tuberculosis (MDR-TB): resistant to at least isoniazid + rifampicin; treat with second-line agents and longer duration.
Practical Example / Mini-Case
Case: A 29-year-old male with known HIV presents with dry cough, progressive dyspnoea over one week, and SpO₂ 88 % on room air. Chest-Xray shows bilateral diffuse interstitial infiltrates. CD4 count is 180 cells/mm³.Question: What is the most likely diagnosis and what is the next best step in management? Answer & Explanation: The most likely diagnosis is Pneumocystis jirovecii pneumonia (PCP). In HIV patients with CD4 <200, PCP is a common opportunistic infection. The next best step is to commence high-dose co-trimoxazole (trimethoprim-sulphamethoxazole) and add corticosteroids if PaO₂ <9.3 kPa. This is a classic pattern likely to appear in the MRCP Part 1 exam.

Practical Study-Tip Checklist
✅ Use time-boxed practice sessions via our Free MRCP MCQs bank: set 30-minute blocks focusing on infectious disease questions.
✅ Build flashcards for drug-mechanism-side-effect pairs (e.g., rifampicin → orange secretions).
✅ Review broad topics every 4 weeks (spaced repetition) to reinforce long-term memory.
✅ After each practice block, review wrong answers and understand why distractors were incorrect.
✅ Group revision around themes (e.g., tropical infections, HIV/opportunistic, antimicrobials) for pattern recognition.
✅ As you progress, simulate full timed paper using Start a mock test to build stamina and exam familiarity.
Common Pitfalls and Fixes
Confusing serology markers: e.g., mis-interpreting hepatitis B serology — fix: draw your own diagram and revise weekly.
Neglecting travel history: many exam vignettes hinge on “returning traveller” clues — fix: always ask the one-sentence travel question in practice.
Ignoring prophylaxis questions: HIV, asplenia, splenectomy contexts often tested — fix: create a mini-list of prophylaxis scenarios.
Overlooking drug side-effects: e.g., ethambutol, rifampicin, linezolid — fix: create a side-effect flash-card deck.
Mis-prioritising time in the exam: Infectious disease questions often appear among multi-system vignettes — fix: practise timed 30-minute blocks to sharpen speed.
FAQs
Q1: How many questions on infectious diseases appear in MRCP Part 1?Approximately 14 questions out of 200 are allocated to infectious diseases according to the official blueprint. thefederation.uk
Q2: Should I focus more on travel/tropical infections or common hospital infections?
Both are important, but for MRCP Part 1 your strongest return comes from common UK-based infections (HIV, TB, endocarditis, sepsis) plus a handful of high-yield tropical/travel infections.
Q3: Are antimicrobial pharmacology questions tested in MRCP Part 1?
Yes — questions include mechanisms of action, resistance and side-effects of antibiotics, antivirals and antifungals as part of infection modules.
Q4: Is microbiology tested separately in MRCP Part 1?
No — microbiology appears integrated into clinical scenarios across specialties; it's not a standalone section but part of the infection/clinical sciences content.
Q5: How does Crack Medicine help with my preparation?
Crack Medicine offers a structured QBank, timed mock tests and lectures focusing on high-yield topics. The system supports exam-style practice, error-review and topic-specific reinforcement.
Ready to start?
Set your infectious disease revision on a solid path: begin with our Free MRCP MCQs to test recall, then use a full mock test to gauge your performance under timed conditions. Visit the main MRCP Part 1 overview page for further structured guidance and unify your study effectively.
Sources
“Format – MRCP(UK) Part 1.” The Federation of the Royal Colleges of Physicians of the UK. https://www.thefederation.uk/examinations/part-1/format thefederation.uk
“MRCP Part 1 revision guide.” BMJ Careers. https://www.bmj.com/careers/article/mrcp-part-1-revision-guide BMJ



Comments